Building on these mechanistic insights, the current in vivo study targeting CVEC-specific ALDH2 overexpression in an obesity–T2DM-driven HFpEF model demonstrates for the first time that directly modulating endothelial oxidative resilience translates into functional cardiac benefits. This evidence concerns the gene ALDH2 and type 2 diabetes mellitus.